Balint, Bettina
Mencacci, Niccolò E.
Valente, Enza Maria
Pisani, Antonio
Rothwell, John
Jankovic, Joseph
Vidailhet, Marie
Bhatia, Kailash P.
Article History
First Online: 20 September 2018
Change Date: 19 October 2018
Change Type: Correction
Change Details: The affiliation for Enza Maria Valente and Antonio Pisani at IRCCS Santa Lucia Foundation, Rome, Italy, has been amended to remove the laboratory designation. Additionally, in Figure 3a, the subthalamic nucleus was incorrectly included in the anatomy of the brain shown and this has been amended.
Competing interests
: E.M.V. holds research grants from the European Research Council (ERC StG260888), Telethon Foundation Italy (GGP13146), the Italian Ministry of Health (Ricerca Finalizzata 2013 NET-2013-02356160) and the University of Pavia (BlueSky Research Grants), receives a stipend from The BMJ as Associate Editor of the Journal of Medical Genetics and has received financial support to speak and/or attend meetings from Zambon. A.P. receives grants from the Italian Ministry of Education, Universities and Research (MIUR, ref PRIN 2015, 2015FNWP34-002) and the Dystonia Medical Research Foundation and received honoraria and financial support to speak or attend meetings from AbbVie, Teva and Union Chimique Belge. M.V. has received travel grants as faculty from The International Parkinson and Movement Disorder Society and the European Academy of Neurology and holds an unrestricted research grant from Merz. J.J. has received research and/or training grants from Adamas Pharmaceuticals, Allergan, Biotie Therapies, CHDI Foundation, Civitas/Acorda Therapeutics, Dystonia Coalition, Dystonia Medical Research Foundation, F. Hoffmann-La Roche, Huntington Study Group, Kyowa Hakko Kirin Pharma, Medtronic Neuromodulation, Merz Pharmaceuticals, Michael J. Fox Foundation for Parkinson Research, National Institutes of Health, Neurocrine Biosciences, NeuroDerm, Nuvelution, Parkinson Disease Foundation, Parkinson Study Group, Pfizer, Prothena Biosciences, Psyadon Pharmaceuticals, Revance Therapeutics, Sangamo BioSciences, St. Jude Medical and Teva. J.J. has served as a consultant or as an advisory committee member for Adamas Pharmaceuticals, Allergan, Merz Pharmaceuticals, Pfizer, Prothena Biosciences, Revance Therapeutics and Teva and has received royalties or other payments from Cambridge, Elsevier, Future Science Group, Hodder Arnold, Lippincott Williams and Wilkins, MedLink, Neurology and Wiley-Blackwell. K.P.B. holds research grants from the National Institute for Health Research, Research for Patient Benefit (NIHR RfPB), a Medical Research Council Wellcome Strategic grant (WT089698) and a grant from Parkinson’s UK (G-1009) and has received honoraria and/or financial support to speak and/or attend meetings from Allergan, Boehringer-Ingelheim, GSK, Ipsen, Lundbeck, Merz, Orion, Sun Pharma and Teva. K.P.B. receives royalties from the Oxford University Press and a stipend for Movement Disorders Clinical Practice editorship. All other authors declare no competing interests.